XNAS
HIND
Market cap1mUSD
Oct 08, Last price
2.03USD
1D
-0.49%
1Q
-9.78%
Jan 2017
-77.06%
IPO
-86.47%
Name
ReShape Lifesciences Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Founded in 2002 and based in San Clemente, California, ReShape Lifesciences Inc. operates as a medical device company dedicated to addressing obesity and metabolic diseases. The company's market extends throughout the United States, Australia, Europe, and globally. Its diverse product lineup features the Lap-Band System, a minimally invasive, long-term solution for severe obesity that offers an alternative to more extensive surgical interventions like gastric bypass or sleeve gastrectomy. Under development is the ReShape Vest system, an investigational, minimally invasive device that is laparoscopically implanted around the stomach to assist obese and morbidly obese patients in losing weight, without cutting or permanently removing parts of the stomach or bypassing any section of the gastrointestinal tract. ReShape also supports patients through the ReShapeCare virtual health coaching program, a telehealth service aimed at promoting healthy lifestyle adjustments for individuals undergoing medically supervised weight management. Additionally, the company is conducting preclinical development for ReShape Diabetes Bloc-Stim Neuromodulation, a technology intended for the treatment of type 2 diabetes mellitus. Among its offerings is the Obalon Balloon System, a swallowable capsule used to monitor and display the balloon's exact position during its placement. The company, initially incorporated as EnteroMedics Inc., changed its name to ReShape Lifesciences Inc. in 2017.
Key people
Andrew P. Rasdal
Chairman of the Board, President, Chief Executive Officer · since 2020
William J. Plovanic
President, Chief Financial Officer · since 2019
Nooshin Hussainy
Vice President - Finance · since 2011
Matthew Norwood
Vice President of Sales · since 2016
Lisa Metzner
Vice President of Marketing · since 2016
Amy VandenBerg
Chief Clinical and Regulatory Affairs Officer · since 2019
Director · since 2017
Raymond V. Dittamore
Independent Director · since 2016
Douglas Fisher
Independent Director · since 2012
Lesley H Howe
Independent Director · since 2016
Sharon Stevenson
Independent Director · since 2008
IPO date
Oct 06, 2016
Employees
40
Domiciled in
US
Incorporated in
US
Legal address
C/O Corporation Service Company
2711 Centerville Road
Suite 400
Wilmington, DE 19808
US
2711 Centerville Road
Suite 400
Wilmington, DE 19808
US
Headquarters
5421 Avenida Encinas
Suite F
Carlsbad, CA 92008
US
Suite F
Carlsbad, CA 92008
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||